Kidney Diseases Clinical Trial
Official title:
Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma
Despite novel treatment options, Renal Cell Carcinoma (RCC) has been characterized by a
constant increase in its mortality and consequently requires an important involvement in
translational research.
The aim of this study is to evaluate the interest of CXCL4, CXCL4L1 and CXCR3 as biomarkers
in localized, locally advanced or metastatic RCC. Indeed these chemokines have shown
anti-angiogenic and anti-tumor properties in experimental models and may be particularly
interesting for prognostic and predictive purposes.
Based on a physiopathological rationale, the use of RCC-directed antiangiogenic therapies
into clinical practice leads to conclusive results and makes RCC a particularly well-suited
tumor type to study factors involved in the angiogenic process. Furthermore the intensive use
of targeted therapies in clinical practice raised new questions about their management.
Therefore the identification of new molecular biomarkers is important:
- to improve the precision of prognostic models currently based on clinical, biological or
histopathological variables
- to identify high risk patients that could benefit from an adjuvant treatment or a closer
postoperative follow-up
- to predict the response to antiangiogenic therapies and therefore identify the drug
which is likely to be the most effective within an ever increasing pharmacopeia
- to follow the therapy as precisely as possible, predict or attest the disease
progression justifying a therapeutic modification
Low CXCL4, CXCL4L1 and CXCR3 tumor expression levels are associated with bad prognosis
factors in RCC. Consequently their interest in RCC is worth being evaluated, in two subgroups
: Localized / locally advanced renal cell carcinoma and Metastatic renal cell carcinoma.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03246984 -
VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ
|
N/A | |
Completed |
NCT03545113 -
Graft-first Versus Fistula-first in Older Patients With End-stage Kidney Disease
|
N/A | |
Recruiting |
NCT05100017 -
Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure
|
N/A | |
Recruiting |
NCT04559321 -
Holmium Vs Trilogy Kidney Stones GUY's 1-2
|
Phase 3 | |
Recruiting |
NCT05036850 -
China Kidney Patient Trials Network
|
||
Completed |
NCT04037436 -
Functional Exercise and Nutrition Education Program for Older Adults
|
N/A | |
Active, not recruiting |
NCT01529658 -
Renal Hypothermia During Partial Nephrectomy
|
N/A | |
Completed |
NCT01679587 -
Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD)
|
Phase 1 | |
Completed |
NCT01155141 -
Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
|
Phase 4 | |
Completed |
NCT00755690 -
Study of Dietary Phosphate and Mineral Homeostasis in Early Chronic Kidney Disease
|
N/A | |
Recruiting |
NCT05759754 -
Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease
|
N/A | |
Completed |
NCT03213158 -
Ixazomib for Desensitization
|
Phase 2 | |
Active, not recruiting |
NCT02237352 -
Mechanisms of Diabetic Nephropathy in Ecuador
|
||
Recruiting |
NCT06067867 -
Kidney and Pregnancy Registry
|
||
Recruiting |
NCT04110080 -
Enhanced Recovery After Surgery in Kidney Transplant Donors
|
N/A | |
Active, not recruiting |
NCT04876963 -
HOLT-ED: Holter-monitoring in End-stage Renal Disease
|
||
Enrolling by invitation |
NCT05324878 -
Honoring Individual Goals and Hopes: Implementing Advance Care Planning for Persons With Kidney Disease on Dialysis
|
||
Not yet recruiting |
NCT03899298 -
Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions
|
Phase 1 | |
Active, not recruiting |
NCT04631965 -
Healthcare Transition of Adolescents With Chronic Health Conditions
|
||
Completed |
NCT03394859 -
Electronic Medical Records and Genomics (eMERGE) Phase III
|